{"id":65553,"date":"2026-05-18T14:43:16","date_gmt":"2026-05-18T06:43:16","guid":{"rendered":"https:\/\/flcube.com\/?p=65553"},"modified":"2026-05-18T14:43:18","modified_gmt":"2026-05-18T06:43:18","slug":"astrazeneca-and-daiichi-sankyos-enhertu-secures-dual-fda-approval-for-her2-positive-early-breast-cancer-neoadjuvant-and-adjuvant-indications-supported-by-landmark-phase-3-data","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65553","title":{"rendered":"AstraZeneca and Daiichi Sankyo&#8217;s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data"},"content":{"rendered":"\n<p><strong>AstraZeneca<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) and <strong>Daiichi Sankyo<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4568:TYO\">TYO: 4568<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>ENHERTU (fam-trastuzumab deruxtecan-nxki)<\/strong> for both <strong>neoadjuvant and adjuvant treatment<\/strong> of patients with <strong>HER2-positive early breast cancer<\/strong>, based on positive results from the <strong>DESTINY-Breast11<\/strong> and <strong>DESTINY-Breast05 Phase 3 trials<\/strong>, respectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Dual indication approval (neoadjuvant + adjuvant)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ENHERTU (fam-trastuzumab deruxtecan-nxki) \u2013 HER2-directed DXd ADC<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>HER2-positive early breast cancer (neoadjuvant and adjuvant settings)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>15 May 2026<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Previously approved in 95+ countries for HER2-positive metastatic breast cancer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-innovation\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> HER2-directed antibody drug conjugate (ADC) with DXd payload<\/li>\n\n\n\n<li><strong>Technology:<\/strong> Specifically engineered with high drug-to-antibody ratio and membrane-permeable payload<\/li>\n\n\n\n<li><strong>Development:<\/strong> Discovered by Daiichi Sankyo, jointly developed and commercialized globally by AstraZeneca and Daiichi Sankyo<\/li>\n\n\n\n<li><strong>Therapeutic Expansion:<\/strong> First ADC to demonstrate efficacy in both neoadjuvant and adjuvant early breast cancer settings<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-dual-phase-3-trial-success\">Clinical Evidence \u2013 Dual Phase 3 Trial Success<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-destiny-breast11-neoadjuvant-setting\">DESTINY-Breast11 (Neoadjuvant Setting)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regimen:<\/strong> ENHERTU followed by THP (docetaxel, trastuzumab, pertuzumab)<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Pathologic complete response (pCR) rate<\/li>\n\n\n\n<li><strong>Results:<\/strong> <strong>67.3% pCR<\/strong> with ENHERTU-based regimen vs. <strong>56.3%<\/strong> with standard ddAC-THP<\/li>\n\n\n\n<li><strong>Statistical Significance:<\/strong> Demonstrated superior pCR rates with clinically meaningful improvement<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-destiny-breast05-adjuvant-setting\">DESTINY-Breast05 (Adjuvant Setting)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population:<\/strong> Patients with residual invasive disease following neoadjuvant therapy<\/li>\n\n\n\n<li><strong>Comparator:<\/strong> Trastuzumab emtansine (T-DM1)<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Invasive disease-free survival (IDFS)<\/li>\n\n\n\n<li><strong>Results:<\/strong> <strong>53% reduction<\/strong> in risk of invasive disease recurrence or death (HR 0.47)<\/li>\n\n\n\n<li><strong>Safety:<\/strong> No new safety concerns identified; consistent with established ENHERTU profile<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<p><strong>HER2-positive breast cancer<\/strong> represents approximately <strong>15-20% of all breast cancer cases<\/strong>, with <strong>early-stage disease<\/strong> affecting over <strong>50,000 patients annually in the US<\/strong>. Current standard of care includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Neoadjuvant: Anthracycline\/taxane-based regimens with dual HER2 blockade<\/li>\n\n\n\n<li>Adjuvant: T-DM1 for patients with residual disease post-neoadjuvant therapy<\/li>\n<\/ul>\n\n\n\n<p><strong>ENHERTU&#8217;s competitive advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual setting approval<\/strong> provides comprehensive treatment continuum from neoadjuvant through adjuvant<\/li>\n\n\n\n<li><strong>Superior pCR rates<\/strong> in neoadjuvant setting may translate to improved long-term outcomes<\/li>\n\n\n\n<li><strong>Significant IDFS benefit<\/strong> in adjuvant setting establishes new standard of care for high-risk patients<\/li>\n\n\n\n<li><strong>Established safety profile<\/strong> from extensive metastatic breast cancer experience<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-implications\">Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Impact:<\/strong> Expected to significantly expand ENHERTU&#8217;s addressable market beyond metastatic setting<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Premium pricing maintained across both new indications reflecting clinical superiority<\/li>\n\n\n\n<li><strong>Market Penetration:<\/strong> Rapid adoption anticipated given strong clinical data and established physician familiarity<\/li>\n\n\n\n<li><strong>Competitive Disruption:<\/strong> Likely to displace T-DM1 as adjuvant standard and challenge anthracycline-based neoadjuvant regimens<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Leadership:<\/strong> Reinforces AstraZeneca and Daiichi Sankyo&#8217;s position as leaders in next-generation antibody drug conjugate development<\/li>\n\n\n\n<li><strong>Treatment Paradigm Shift:<\/strong> Establishes ENHERTU as backbone therapy across the entire HER2-positive breast cancer continuum<\/li>\n\n\n\n<li><strong>Global Harmonization:<\/strong> US approval supports ongoing regulatory submissions in other major markets<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success validates DXd ADC platform for early-stage disease applications beyond metastatic settings<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial performance for ENHERTU. Actual results may differ due to risks including market adoption rates, competitive dynamics, and reimbursement decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65561,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,130,194,83,4621,15,978],"class_list":["post-65553","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-astrazeneca","tag-daiichi-sankyo","tag-her2","tag-nyse-azn","tag-product-approvals","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca and Daiichi Sankyo&#039;s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration (FDA) has approved ENHERTU (fam-trastuzumab deruxtecan-nxki) for both neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer, based on positive results from the DESTINY-Breast11 and DESTINY-Breast05 Phase 3 trials, respectively.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65553\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca and Daiichi Sankyo&#039;s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration (FDA) has approved ENHERTU (fam-trastuzumab deruxtecan-nxki) for both neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer, based on positive results from the DESTINY-Breast11 and DESTINY-Breast05 Phase 3 trials, respectively.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65553\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-18T06:43:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-18T06:43:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65553#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65553\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca and Daiichi Sankyo&#8217;s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data\",\"datePublished\":\"2026-05-18T06:43:16+00:00\",\"dateModified\":\"2026-05-18T06:43:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65553\"},\"wordCount\":515,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65553#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1803.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"AstraZeneca\",\"Daiichi Sankyo\",\"HER2\",\"NYSE:\u202fAZN\",\"Product approvals\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65553#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65553\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65553\",\"name\":\"AstraZeneca and Daiichi Sankyo's ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65553#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65553#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1803.webp\",\"datePublished\":\"2026-05-18T06:43:16+00:00\",\"dateModified\":\"2026-05-18T06:43:18+00:00\",\"description\":\"AstraZeneca (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration (FDA) has approved ENHERTU (fam-trastuzumab deruxtecan-nxki) for both neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer, based on positive results from the DESTINY-Breast11 and DESTINY-Breast05 Phase 3 trials, respectively.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65553#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65553\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65553#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1803.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca and Daiichi Sankyo's ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65553#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca and Daiichi Sankyo&#8217;s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca and Daiichi Sankyo's ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration (FDA) has approved ENHERTU (fam-trastuzumab deruxtecan-nxki) for both neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer, based on positive results from the DESTINY-Breast11 and DESTINY-Breast05 Phase 3 trials, respectively.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65553","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca and Daiichi Sankyo's ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data","og_description":"AstraZeneca (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration (FDA) has approved ENHERTU (fam-trastuzumab deruxtecan-nxki) for both neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer, based on positive results from the DESTINY-Breast11 and DESTINY-Breast05 Phase 3 trials, respectively.","og_url":"https:\/\/flcube.com\/?p=65553","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-18T06:43:16+00:00","article_modified_time":"2026-05-18T06:43:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65553#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65553"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca and Daiichi Sankyo&#8217;s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data","datePublished":"2026-05-18T06:43:16+00:00","dateModified":"2026-05-18T06:43:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65553"},"wordCount":515,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65553#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1803.webp","keywords":["ADC \/ XDC","AstraZeneca","Daiichi Sankyo","HER2","NYSE:\u202fAZN","Product approvals","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65553#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65553","url":"https:\/\/flcube.com\/?p=65553","name":"AstraZeneca and Daiichi Sankyo's ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65553#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65553#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1803.webp","datePublished":"2026-05-18T06:43:16+00:00","dateModified":"2026-05-18T06:43:18+00:00","description":"AstraZeneca (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration (FDA) has approved ENHERTU (fam-trastuzumab deruxtecan-nxki) for both neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer, based on positive results from the DESTINY-Breast11 and DESTINY-Breast05 Phase 3 trials, respectively.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65553#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65553"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65553#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1803.webp","width":1080,"height":608,"caption":"AstraZeneca and Daiichi Sankyo's ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65553#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca and Daiichi Sankyo&#8217;s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer \u2013 Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65553"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65553\/revisions"}],"predecessor-version":[{"id":65562,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65553\/revisions\/65562"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65561"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}